Cargando…
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Despite the initial benefits of treating HER2-amplified breast cancer patients with the tyrosine kinase inhibitor lapatinib, resistance inevitably develops. Here we report that lapatinib induces the degradation of the nuclear receptor ERRα, a master regulator of cellular metabolism, and that the exp...
Autores principales: | Deblois, Geneviève, Smith, Harvey W., Tam, Ingrid S., Gravel, Simon-Pierre, Caron, Maxime, Savage, Paul, Labbé, David P., Bégin, Louis R., Tremblay, Michel L., Park, Morag, Bourque, Guillaume, St-Pierre, Julie, Muller, William J., Giguère, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945959/ https://www.ncbi.nlm.nih.gov/pubmed/27402251 http://dx.doi.org/10.1038/ncomms12156 |
Ejemplares similares
-
ERRα fosters running endurance by driving myofiber aerobic transformation and fuel efficiency
por: Xia, Hui, et al.
Publicado: (2023) -
Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4
por: Vernier, Mathieu, et al.
Publicado: (2020) -
Transcriptional Regulation of ROS Homeostasis by the ERR Subfamily of Nuclear Receptors
por: Scholtes, Charlotte, et al.
Publicado: (2021) -
ERRα activates SHMT2 transcription to enhance the resistance of breast cancer to lapatinib via modulating the mitochondrial metabolic adaption
por: Li, Xin, et al.
Publicado: (2020) -
OR14-04 A Novel ERRα-Dependent Insulin Signaling Pathway
por: Xia, Hui, et al.
Publicado: (2020)